Bavarian Nordic AS
BV3
Company Profile
Business description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
Contact
Philip Heymans Alle 3
Hellerup2900
DNKT: +45 33268383
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,667
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.20 | 1.30 | -0.01% |
| CAC 40 | 7,886.51 | 10.42 | -0.13% |
| DAX 40 | 23,626.37 | 122.49 | -0.52% |
| Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
| FTSE 100 | 9,252.88 | 24.15 | -0.26% |
| HKSE | 26,438.51 | 8.05 | -0.03% |
| NASDAQ | 22,348.75 | 207.64 | 0.94% |
| Nikkei 225 | 44,902.27 | 134.15 | 0.30% |
| NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
| S&P 500 | 6,615.28 | 30.99 | 0.47% |
| S&P/ASX 200 | 8,877.70 | 3.00 | -0.03% |
| SSE Composite Index | 3,861.86 | 1.36 | 0.04% |